The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60 ...

The two-dose vaccine has been shown to have benefits beyond just developing shingles, although that alone should be impetus ...

The new memos from the Food and Drug Administration show how the agency’s vaccine chief, Dr. Vinay Prasad, personally ...

The new RSV recommendation calls for a single dose of vaccine for adults age 50 to 59 years who are at increased risk of ...

The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a lower group of adults aged 18 to 59 years at increased risk for disease.

According to a new poll, the subject appears to be less controversial than the loud minority would have us believe.

A new multi-state study led by the Centers for Disease Control and Prevention's (CDC) VISION Network—including Regenstrief ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

This builds upon its initial approval in May 2024 for adults aged 60 years and older, which makes mRESVIA the second approved ...

Medical staff in Western Australia have been warned after reports of the wrong immunisations being given to patients. The ...